# Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma

> **NCT01618253** · PHASE1 · WITHDRAWN · sponsor: **Medical College of Wisconsin**

## Conditions studied

- Hepatocellular Carcinoma
- Hepatocellular Cancer
- Hepatoma
- Liver Cancer

## Interventions

- **DRUG:** Sorafenib
- **RADIATION:** Conventional fractionation (2 Gy per day) external beam radiation therapy

## Key facts

- **NCT ID:** NCT01618253
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-06
- **Primary completion:** 2015-06
- **Final completion:** 2016-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Closed due to poor accrual.
- **Last updated:** 2013-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01618253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01618253, "Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01618253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*